Xintela AB (Sweden) Profile

SEK 0.04  1.34%

Xintela AB Summary

Xintela AB (XINT) is traded on Stockholm Stock Exchange in Sweden. It is located in Scheelev?gen 2 and employs 12 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 91.1 M. Xintela AB operates under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 30.37 M outstanding shares. The company has accumulated about 12.53 M in cash with (14.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42.
Check Xintela AB Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 3.02HorizonTargetOdds Above 3.02
?%30 days 3.02 ?%
Based on normal probability distribution, the odds of Xintela AB to move above current price in 30 days from now is about 0.0% (This Xintela AB probability density function shows the probability of Xintela AB Stock to fall within a particular range of prices over 30 days) .

Key Fundamentals

Xintela AB Against Markets

Current Ratings

Xintela AB 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Xintela AB are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Xintela AB , a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company was founded in 2009 and is based in Lund, Sweden. Xintela AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange. more
NameXintela AB
CEOEvy LundgrenAkerlundView All
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentSweden Stock View All
Business AddressScheelev?gen 2
ExchangeStockholm Stock Exchange
IndustryPharmaceuticals And Biosciences
CurrencySEK - Swedish Kronor

Diversify with Xintela AB

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Xintela AB to your portfolio


Xintela AB Corporate Directors
Sven Kili Director
Liselotte Theorell Director Product Development and Quality Management
Keld Soendergaard Director
See also Your Current Watchlist. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.